logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

Capivasertib+fulvestrant doubles PFS in AI-resistant advanced breast cancer

Phase 2 FAKTION trial is the first to test an AKT inhibitor.